Ziya Clinical Consulting Ltd Takes Shape as an Active Research Entity
A new UK company, Ziya Clinical Consulting Ltd, is now listed as active on Companies House with a registered office in St Albans, Hertfordshire. The filing places the business within a research-oriented corporate structure rather than a clinical provider register, and its declared activity sits under Other research and experimental development on natural sciences and engineering.
The company was incorporated on 30 March 2026 as a private limited company. Its registered office is 27 Alban Row, Verulam Road, St Albans, Hertfordshire, AL3 4DG. On the public register, the company status is active.
A Corporate Filing, Not a Clinical Data Release
This record contains no trial data, no patient cohort, no prescribing information, and no safety signal. What it does provide is a formal business marker for an entity positioned in research and development, a sector that often sits close to preclinical science, translational work, laboratory methods, and technical consultancy.
The registered SIC code, 72190, is broad. In practical terms, it captures organizations involved in experimental development in natural sciences and engineering without specifying a therapeutic area, device class, or disease focus. In the absence of further filings, the public record stops at that level of detail.
A single sentence in the corporate register can still matter in the research ecosystem. A company set up under this classification may later expand into contract research, regulatory support, scientific advisory work, product development, or technical services, but none of those activities are spelled out here. The filing only confirms the legal entity and the sector it has chosen for registration.
What the Filing Date and Deadlines Establish
The incorporation date of 30 March 2026 fixes the company’s legal birth in the UK register. Two first reporting milestones are already visible: the first accounts are made up to 31 March 2027 and are due by 30 December 2027, while the first confirmation statement date is 29 March 2027, due by 12 April 2027.
Those dates do not reveal scientific output. They do, however, define the cadence of statutory disclosure that will determine how much more becomes visible about the company’s structure, officers, and activity in the future. Until then, the register offers only the basic frame: active status, private limited company status, a registered address, and a research-and-development classification.
Why the SIC Code Matters for Interpretation
The SIC code is the clearest clue in the filing. Code 72190 points to research and experimental development across natural sciences and engineering, which is materially different from a conventional clinical practice or patient-facing medical service. It suggests an entity set up for innovation, experimentation, or scientific services rather than direct care delivery.
In medical journalism, that distinction matters because company registration data can easily be mistaken for evidence of clinical activity. Here, there is no such evidence. The company name includes the word “clinical,” yet the public record does not establish any licensed healthcare service, no clinical program, and no regulated treatment offering. The legal filing is better read as a business formation notice than as a healthcare announcement.
That restraint is important. In healthcare reporting, the presence of a medical-sounding name should never be treated as proof of clinical operations. The register does not go that far, and neither should a responsible read of it.
The Public Record Stops at Formation
The register also shows the usual Companies House functions: a filing history, officer information, and a company overview page. Those links indicate that additional corporate details may be available through the UK registry, but the material provided here does not include them. No officer names are visible in the supplied text, and no ownership structure appears in the excerpt.
The absence of those details limits the clinical relevance of the filing. Without named directors, without a stated therapeutic focus, and without any linked scientific output, the company remains a general research entity on paper. The public record does not support stronger claims than that.
For readers scanning for medical substance, the most defensible takeaway is simple: Ziya Clinical Consulting Ltd is an active UK private limited company registered in a research and experimental development category. Its current public profile is administrative rather than clinical, and no patient-facing or disease-specific activity is documented in the supplied record.
What Can Be Said, and What Cannot
The company has a valid registration, a named office, a clear SIC code, and statutory reporting deadlines. Those are the facts.
No therapeutic claims can be attached to them. No patient population can be inferred. No safety profile exists because no intervention is described. The filing is useful as a corporate identifier, but it does not provide a basis for medical interpretation beyond the broad research designation attached to the business.